Patents by Inventor Haiyan Jiang

Haiyan Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20230322900
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: December 12, 2022
    Publication date: October 12, 2023
    Inventors: Volker Schellenberger, Pei-Yun Chang, Fatbardha Varfaj, Sheng Ding, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, John Kulman, Tongyao Liu, Garabet G. Toby, Haiyan Jiang, Robert Peters, Deping Wang, Baisong Mei
  • Assays to monitor bleeding disorders
    Patent number: 11747351
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: September 5, 2023
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20230019286
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: April 26, 2021
    Publication date: January 19, 2023
    Inventors: Volker SCHELLENBERGER, Pei-Yun CHANG, Fatbardha VARFAJ, John KULMAN, Tongyao LIU, Garabet G. TOBY, Haiyan JIANG, Robert PETERS, Deping WANG, Baisong MEI, Joshua SILVERMAN, Chia-Wei WANG, Benjamin SPINK, Nathan GEETHING
  • CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF
    Publication number: 20230011438
    Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
    Type: Application
    Filed: May 27, 2022
    Publication date: January 12, 2023
    Inventors: Ekta Seth CHHABRA, Tongyao LIU, Robert T. PETERS, Haiyan JIANG
  • METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY
    Publication number: 20230002828
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Application
    Filed: February 25, 2022
    Publication date: January 5, 2023
    Inventors: Haiyan JIANG, Tongyao LIU, Sriram KRISHNAMOORTHY, Neil JOSEPHSON, Glenn PIERCE
  • FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20220265780
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 25, 2022
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert PETERS
  • Chimeric factor VIII polypeptides and uses thereof
    Patent number: 11370827
    Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: June 28, 2022
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T Peters, Haiyan Jiang
  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
    Patent number: 11286528
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 29, 2022
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 11266720
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: March 8, 2022
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • METHODS OF USING FIX POLYPEPTIDES
    Publication number: 20220064622
    Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
    Type: Application
    Filed: July 16, 2021
    Publication date: March 3, 2022
    Inventors: Glenn PIERCE, Samantha TRUEX, Robert T. PETERS, Haiyan JIANG, Mark BRADER
  • FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF
    Publication number: 20220056108
    Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein.
    Type: Application
    Filed: June 25, 2021
    Publication date: February 24, 2022
    Inventors: Ekta Seth CHHABRA, Tongyao LIU, Pei-yun CHANG, Robert T. PETERS, John KULMAN, Haiyan JIANG
  • Methods of using FIX polypeptides
    Patent number: 11225650
    Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 18, 2022
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang, Mark Brader
  • Methods of using FIX polypeptides
    Patent number: 11193116
    Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: December 7, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang, Mark Brader
  • Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
    Patent number: 11091534
    Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: August 17, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Ekta Seth Chhabra, Tongyao Liu, Pei-yun Chang, Robert T. Peters, John Kulman, Haiyan Jiang
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20210220476
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 22, 2021
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert T. PETERS
  • FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210023185
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 28, 2021
    Inventors: Glenn PIERCE, Samantha TRUEX, Robert T. PETERS, Haiyan JIANG
  • Factor IX polypeptides and methods of use thereof
    Patent number: 10898554
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: January 26, 2021
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210008178
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: June 22, 2020
    Publication date: January 14, 2021
    Inventors: Glenn PIERCE, Samantha TRUEX, Robert T. PETERS, Haiyan JIANG
  • Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 10881742
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 5, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert T. Peters
  • ASSAYS TO MONITOR BLEEDING DISORDERS
    Publication number: 20200386774
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
    Type: Application
    Filed: April 14, 2020
    Publication date: December 10, 2020
    Inventors: Jurg SOMMER, Haiyan JIANG, Xin ZHANG, Buyue YANG, Glenn PIERCE